MedTrace Logo

Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study

NCT07191756 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-09-25

No results posted yet for this study

Summary

Background:

Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole. However, more real-world data is needed to directly compare how well they work and how safe they are for patients.

What is the purpose of this study? The main goal of this research study is to compare the effectiveness and safety of amphotericin B versus isavuconazole in treating mucormycosis. Investigators will look at which medicine leads to better survival rates and fewer serious side effects.

How will the study be done? This is a retrospective study. This means investigators will look back at information that has already been collected. Investigators will analyze data from the medical records of patients who were treated for mucormycosis at three hospitals. Investigators will also review and combine findings from relevant studies published on PubMed.

What will the researchers measure?

Investigators will measure and compare:

How long patients survived after treatment (survival rates).

Whether the infection was successfully cured or controlled (treatment response).

What kinds of side effects (like kidney problems or liver issues) patients experienced with each medicine.

What are the possible benefits of this study? This study will not directly benefit the participants whose records are reviewed. However, investigators hope that what investigators learn will help doctors make better treatment decisions for future patients with mucormycosis by providing clearer evidence on the best choice of medicine.

Conditions

  • Mucormycosis

Interventions

DRUG

Amphotericin B

This is a retrospective observational study. Patients in this cohort received various formulations of amphotericin B as part of their standard medical care.

DRUG

Isavuconazole

This is a retrospective observational study. Patients in this cohort received isavuconazole as part of their standard medical care.

Sponsors & Collaborators

  • Guangzhou Medical University

    collaborator OTHER

  • Qiu Ye

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-15
Primary Completion
2025-07-21
Completion
2025-09-25
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07191756 on ClinicalTrials.gov